Pralnacasan

Description: Pralnacasan inhibits proinflammatory cytokines IL-18, IL-1beta , and IFN-gamma. Pralnacasan is an effective, non-peptide, and orally active interleukin-1beta converting enzyme inhibitor (Ki: 1.4 nM). Pralnacasan has the potential for osteoarthritis and rheumatoid arthritis treatment. Target: Others. Smiles: CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN2N1C(=O)[C@H](CCC2=O)NC(=O)c1nccc2ccccc12. References: Rudolphi K, et al. Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage. 2003 Oct,11(10):738-46.